Logo for Infant Bacterial Therapeutics

Infant Bacterial Therapeutics Investor Relations Material

Latest events

Logo for Infant Bacterial Therapeutics

Study Update

Infant Bacterial Therapeutics
Logo for Infant Bacterial Therapeutics

Q3 2024

14 Nov, 2024
Logo for Infant Bacterial Therapeutics

Study Update

3 Sep, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Infant Bacterial Therapeutics

Access all reports
Infant Bacterial Therapeutics AB, a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company focuses on late onset neonatal infection, a disease caused by an imbalance in the infant’s gut microbiota. Its lead drug candidate is IBP-9414 is being developed for the treatment of lactobacillus plantarum, enterococcus faecium and escherichia coli infections in preterm infants. The company was formerly known as Enterome AB and changed its name to Infant Bacterial Therapeutics AB in August 2012. Infant Bacterial Therapeutics AB is based in Stockholm, Sweden. As of March 4, 2015, Infant Bacterial Therapeutics AB operates as a subsidiary of Tim Medical Holdings Limited.